ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti +3 more
wiley +1 more source
HAEMFIX: Impact of Switching From SHL-FIX to EHL-FIX in Patients With Haemophilia B. [PDF]
Lonardi J +11 more
europepmc +1 more source
Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice? [PDF]
Farid S, Sewaralthahab S, Smith HP.
europepmc +1 more source
Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A
ABSTRACT Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success.
Marcus Fager Ferrari +5 more
wiley +1 more source
Benign endobronchial lesion causing massive haemoptysis in a patient with haemophilia B. [PDF]
Mosalem O +3 more
europepmc +1 more source
ABSTRACT Aim To identify and map evidence on factors that influence nurses' engagement in clinical research. Design A scoping review was conducted in accordance with the JBI methodology. Methods First, titles and abstracts of articles, then full‐text articles, were screened by two independent researchers against inclusion and exclusion criteria.
Lyndsay Jerusha Mackay +9 more
wiley +1 more source
Safety, Efficacy and Treatment Patterns of rIX-FP in Previously Untreated Paediatric Haemophilia B Patients: A Retrospective Chart Review in Japan. [PDF]
Nogami K, Nagae C, Yono M, Terasaka N.
europepmc +1 more source
Vitamin K deficiency bleeding of newborn masquerading haemophilia B. [PDF]
Kumar M, Kumar S, Bajpayi S, Kumari R.
europepmc +1 more source
Perfusion Cell Cultures: Is the Technology Worthwhile for Biopharmaceutical Production?
The biotechnology industry is pursuing innovation and robust production, yet many biopharmaceuticals are manufactured from batch or fed‐batch cell cultures. Perfusion processes, offering higher yields and efficiency, remain underused despite their maturity.
Francesco Iannacci, Mattia Sponchioni
wiley +1 more source
Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX. [PDF]
Park YS +16 more
europepmc +1 more source

